HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce significant advancements in its Good Manufacturing Practice (GMP) stability programs.
Related news for (HYTNF)
- HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
- HYTN Awarded Drug Establishment License from Health Canada, Expanding GMP Capabilities
- HYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
- HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities